Insider Selling: Cypherpunk Technologies (NASDAQ:CYPH) Director Sells $34,400.00 in Stock

Key Points

• Director Thomas John Dietz sold 20,000 Cypherpunk Technologies shares at an average price of $1.72, receiving $34,400 and reducing his direct holdings by 13.11% to 132,500 shares.
• Cypherpunk shares rose 16% to $1.89 in Thursday trading, alongside unusually high volume of 14.4 million shares versus an average of 3.8 million.
• Institutional ownership stands at 30.46%, while analyst sentiment remains mixed: the stock has a consensus “Hold” rating and a $1.60 average price target.

Cypherpunk Technologies (NASDAQ:CYPH - Get Free Report) Director Thomas John Dietz sold 20,000 shares of the stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $1.72, for a total transaction of $34,400.00. Following the sale, the director directly owned 132,500 shares in the company, valued at approximately $227,900. This represents a 13.11% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Cypherpunk Technologies Stock Up 16.0%

CYPH stock traded up $0.26 during trading on Thursday, hitting $1.89. The company had a trading volume of 14,437,919 shares, compared to its average volume of 3,801,312. The stock has a market cap of $203.67 million, a price-to-earnings ratio of 3.37 and a beta of 0.09. Cypherpunk Technologies has a 12 month low of $0.27 and a 12 month high of $3.70. The firm has a 50-day moving average price of $0.77 and a 200-day moving average price of $0.81.

Cypherpunk Technologies (NASDAQ:CYPH - Get Free Report) last posted its quarterly earnings results on Wednesday, August 12th. The company reported $0.18 earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Cypherpunk Technologies

Institutional investors and hedge funds have recently modified their holdings of the company. Simplify Asset Management Inc. bought a new position in Cypherpunk Technologies during the fourth quarter worth about $2,172,000. Acadian Asset Management LLC raised its position in shares of Cypherpunk Technologies by 470.4% in the first quarter. Acadian Asset Management LLC now owns 1,280,531 shares of the company's stock valued at $389,000 after purchasing an additional 1,056,047 shares during the period. Renaissance Technologies LLC acquired a new stake in shares of Cypherpunk Technologies during the 1st quarter worth about $576,000. Geode Capital Management LLC acquired a new stake in shares of Cypherpunk Technologies during the 4th quarter worth about $615,000. Finally, State Street Corp bought a new stake in shares of Cypherpunk Technologies during the fourth quarter worth approximately $163,000. 30.46% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on CYPH. Wall Street Zen upgraded shares of Cypherpunk Technologies from a "sell" rating to a "hold" rating in a report on Saturday, July 4th. Weiss Ratings upgraded shares of Cypherpunk Technologies from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Monday, August 17th. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $1.60 price target on shares of Cypherpunk Technologies in a research note on Thursday. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $1.60.

About Cypherpunk Technologies

Cypherpunk Technologies Inc, previously known as Leap Therapeutics, Inc, is a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The company’s research platform centers on modulating the tumor microenvironment to enhance anti-tumor immune responses. Cypherpunk’s proprietary pipeline includes DKN-01, a monoclonal antibody designed to neutralize Dickkopf-1 (DKK1), a protein implicated in tumor growth and immune evasion.

DKN-01 is being evaluated both as a monotherapy and in combination with checkpoint inhibitors such as pembrolizumab across multiple solid tumor indications, including gastroesophageal, pancreatic and other advanced malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source